Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech goes beyond Infinity with FDA OK to sell Hedgehog inhibitor for advanced BCC

This article was originally published in Scrip

Executive Summary

Well ahead of its PDUFA deadline of 8 March, the US FDA on January 30 gave Roche's Genentech arm the green light to sell vismodegib as the first nonsurgical treatment for advanced basal cell carcinoma (BCC). The company said that the once-a-day capsule will be on the US market under the trade name Erivedge before mid-February. Last month Roche filed for approval of the drug with the EMA (, 23 December 2011). It is intended for the small group of BCC patients for whom the condition is not treated soon enough or in whom it returns in the same location after treatment.


Related Content

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
J.P. Morgan Executive Roundtable, Part 2: Women In Biopharma And The Path Forward
J.P. Morgan Executive Roundtable, Part 1: How To Help Women Move Into The Biopharma C-Suite


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts